In rare cases when patients do not qualify for clinical trials and have exhausted all available treatment options, regulators may grant permission for Purdue to provide a treating physician with an unapproved medicine. Such individual use of an unlicensed investigational medicine is often called “compassionate use” or “expanded access”, but may go by other names.
For information from the FDAa V 影在線 Av影片 about expanded access in the U.S., .
Who is eligible for Purdue’s Expanded Access Program?
All of the following criteria must be met in order to be considered for expanded access to Purdue’s investigational medicines:
- The patient has a serious or immediately life-threatening disease or condition.
- There is no comparable or satisfactory alternative therapy for the disease or condition, or the patient has undergone appropriate standard treatment without success.
- The patient is ineligible for participation in any ongoing clinical study of the investigational medicine.
- There is sufficient evidence or understanding of a potential patient benefit from the use of the investigational medicine to justify its potential risks.
- The medicine must be part of an active and ongoing development process, and expanded access would not interfere within its development.
- There is an adequate supply of the medicine to perform necessary clinical studies as well as provide expanded access.
Patients interested in expanded access to Purdue’s investigational medicines should speak to their physician.